Halozyme Therapeutics Target of Unusually Large Options Trading (HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the target of some unusual options trading on Wednesday. Investors bought 6,543 put options on the stock. This represents an increase of 1,214% compared to the average volume of 498 put options.

Several brokerages have recently commented on HALO. BidaskClub downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, December 25th. BMO Capital Markets boosted their price objective on Halozyme Therapeutics from $14.00 to $15.00 and gave the company a “market perform” rating in a research report on Friday, September 15th. Deutsche Bank lifted their target price on Halozyme Therapeutics to $20.00 and gave the stock a “buy” rating in a report on Friday, September 15th. Finally, Piper Jaffray Companies lifted their target price on Halozyme Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Monday, October 16th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $19.14.

Shares of Halozyme Therapeutics (NASDAQ:HALO) opened at $20.36 on Friday. Halozyme Therapeutics has a twelve month low of $10.74 and a twelve month high of $21.13. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.46 and a quick ratio of 3.37. The stock has a market capitalization of $2,890.00, a PE ratio of -29.94 and a beta of 2.09.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by ($0.04). Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The firm had revenue of $63.73 million during the quarter, compared to the consensus estimate of $58.95 million. During the same period last year, the firm posted ($0.23) earnings per share. The company’s revenue for the quarter was up 100.1% compared to the same quarter last year. research analysts anticipate that Halozyme Therapeutics will post 0.2 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of HALO. Schwab Charles Investment Management Inc. increased its holdings in shares of Halozyme Therapeutics by 9.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 511,806 shares of the biopharmaceutical company’s stock worth $6,562,000 after purchasing an additional 46,040 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Halozyme Therapeutics by 353.8% in the second quarter. First Trust Advisors LP now owns 71,106 shares of the biopharmaceutical company’s stock worth $912,000 after purchasing an additional 55,437 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Halozyme Therapeutics by 3.0% in the second quarter. Bank of New York Mellon Corp now owns 1,861,571 shares of the biopharmaceutical company’s stock worth $23,866,000 after purchasing an additional 55,081 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Halozyme Therapeutics by 14.5% in the second quarter. Legal & General Group Plc now owns 44,116 shares of the biopharmaceutical company’s stock worth $567,000 after purchasing an additional 5,585 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its holdings in shares of Halozyme Therapeutics by 619.3% in the second quarter. BNP Paribas Arbitrage SA now owns 17,047 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 14,677 shares during the last quarter. 84.45% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Halozyme Therapeutics Target of Unusually Large Options Trading (HALO)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/13/halozyme-therapeutics-target-of-unusually-large-options-trading-halo.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit